Table 2.

Treatment‐related adverse events^a

	1.0 mg/kg q2w (Group 1, n = 4)	3.0 mg/kg q2w (Group 2, n = 4)	10 mg/kg q2w (Group 3, n = 4)	15 mg/kg q3w (Group 4, n = 6)	20 mg/kg q4w (Group 5, n = 4)	Total (N = 22)
Any trAE, n (%)	3 (75)	3 (75)	3 (75)	5 (83)	2 (50)	16 (73)
Rash	1 (25)	0	1 (25)	1 (17)	1 (25)	4 (18)
Pruritus	0	2 (50)	0	1 (17)	0	3 (14)
Constipation	0	2 (50)	0	1 (17)	0	3 (14)
Nausea	0	1 (25)	0	0	2 (50)	3 (14)
Stomatitis	0	1 (25)	0	1 (17)	1 (25)	3 (14)
Pyrexia	1 (25)	0	1 (25)	0	1 (25)	3 (14)

q2w, every 2 weeks; q3w, every 3 weeks; q4w, every 4 weeks; trAE, treatment‐related adverse event.

^aSafety analysis set.